Ultra-high performance SPECT systems announced by MILabs

MILabs,  B.V.  the  Netherlands‐based  innovator  and  manufacturer  of  pre‐clinical  SPECT/PET/CT imaging devices announces the release of the Plus! Systems: the U‐SPECT+  and U‐SPECT+ /CT.

Both  systems  achieve  for  the  first  time  reconstructed  SPECT  resolution  of  ¼mm  utilizing  a  new, super high‐resolution collimator design. Significant resolution improvements (up to 15%) were also realized  for  the  existing  U‐SPECT  multi‐pinhole  collimator  family  that  is  based  on  MILabs’ 
TM proprietary M5  dual‐stage technology. Resolution gains were validated using Jaszczak phantom measurements  while  superior  in  vivo  results  are  currently  demonstrated  by  investigators  in cardiac,  neuroscience,  oncology  and  pharmaceutical  research,  which  will  open  new  frontiers  in 
these fields.

Additionally,  MILabs  introduces  ultra‐high‐sensitive  SPECT  capability  of    >12,000  cps/MBq.  This enables  extremely  low‐dose  experiments  and  accurate  analysis  of  very  fast  tracer  dynamics. MILabs now also offers new imaging beds and cells optimized for obesity studies.

Also  with  these  Plus!  systems,  MILabs  announces  dynamic  sub‐half‐minute  whole‐body  mouse SPECT.    This  novel  technique  is  accomplished  with  the  benefit  of  the  MILabs  highly  stable stationary detector design which is heralded by many researchers involved in e.g. pharmacokinetic 

Extending  the  U‐SPECT/CT  and  VECTor/CT  hybrid  SPECT/PET  modality  functionality,  MILabs announces with the Plus! the integration of data from most high‐performance MRI platforms. 

Central  to  the  new  performance  Plus!  enhancements  is  MILabs  fully  3D  model‐based    U‐RECON image  reconstruction  employing  accurate  attenuation  correction  and  scientifically  validated system modeling for optimized resolution recovery and quantification for single and multi‐isotope 
SPECT and simultaneous SPECT/PET.

New Plus! Functionalities are available for all MILabs systems and some as upgrades for existing U‐SPECT and VECTor systems.

Please contact MILabs on how these advanced benefits could enable new research capabilities in your imaging lab.

About MILabs, B.V.

MILabs provides high‐end pre clinical molecular imaging solutions (SPECT/PET/CT) for biomedical and pharmaceutical research. Today these systems contribute worldwide to the development of new diagnostic solutions and therapies for diseases such as cancer, cardiac and neurodegenerative diseases, depression  and diabetes. U‐SPECT/CT provides the fastest, most sensitive and highest resolution small‐animal SPECT currently available. Recently MILabs introduced VECTor and VECTor/CT providing extremely user friendly, fully integrated and simultaneous ultra‐high resolution SPECT/PET.


Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    MILabs. (2019, June 19). Ultra-high performance SPECT systems announced by MILabs. News-Medical. Retrieved on November 28, 2020 from https://www.news-medical.net/news/20121029/Ultra-high-performance-SPECT-systems-announced-by-MILabs.aspx.

  • MLA

    MILabs. "Ultra-high performance SPECT systems announced by MILabs". News-Medical. 28 November 2020. <https://www.news-medical.net/news/20121029/Ultra-high-performance-SPECT-systems-announced-by-MILabs.aspx>.

  • Chicago

    MILabs. "Ultra-high performance SPECT systems announced by MILabs". News-Medical. https://www.news-medical.net/news/20121029/Ultra-high-performance-SPECT-systems-announced-by-MILabs.aspx. (accessed November 28, 2020).

  • Harvard

    MILabs. 2019. Ultra-high performance SPECT systems announced by MILabs. News-Medical, viewed 28 November 2020, https://www.news-medical.net/news/20121029/Ultra-high-performance-SPECT-systems-announced-by-MILabs.aspx.


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
You might also like... ×
LBIC acquires MILabs' new diagnostic X-Ray CT system to extend its preclinical imaging capabilities